I hope your joking! According to the analysts this company is dead money till late 2004 at best. Personally, I think 2005/2006 is more likely. The FDA doesn't get paid to be expediant, they get paid to be right. After all, wether they approve the cerus processes or not, it won't make a difference in their paycheck.
I think it's funny that the analyst only down-graded it one notch. I think they do that only to save face. If they could, I bet they would go all the way to strong sell since this company has no meaningful income for the foresable future. But then everyone would see what blithering idiots they are.
I wouldn't consider buying this stock this year. I think it will be available at $2/share next year, if it is still listed.
Baxter will make this brilliant technology work bigtime. The fact that they are behind schedule is a concern but not a real problem. Baxter has loaned CERS $50m which is not repaid until 2008 suggests Baxters confidence in CERS.Baxter does not loan such heavy money unless they are certain about major returns for their own bottom line. In addition this system is badly needed by society.